Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Currently, ANSM recommendations govern FMT (Fecal Microbiota Transplantation) in clinical trials. The collection and validation of these stool donations as part of the trials is complex and not very efficient. It therefore seems essential to identify the limiting factors and the characteristics of Healthy Volunteer Donors to optimize the number of valid stool donations.
Full description
If the ANSM recommendations govern FMT (Fecal Microbiota Transplantation) in clinical trials, the selection, inclusion of Healthy Volunteer Donors (HVD), then the collection and validation of these stool donations is complex and not very effective. New recommendations related to COVID-19 make this process even more complex. It therefore seems essential to identify the limiting factors and the characteristics of HVD to optimize the number of valid stool donations.
Healthy voluntary donors of stools for the preparation of TMF (Healthy Volunteer Donors, -TMF) for trials to evaluate its effectiveness in various pathologies will be selected, included and followed in a common protocol (ANSM agreement obtained) in order to facilitate this entire process and pool resources. This will allow us to describe the clinical characteristics and lifestyle habits of Healthy Volunteer Donors associated with the validity of stool donations.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Definitive non-inclusion criteria:
Infectious risk :
Known HIV, HBV, HCV, HTLV infection
Residence of more than 2 years in the intertropics zone within the previous 5 years
Hospitalization abroad for more than 24 hours in the last 12 months (including a member of the healthy volunteers donor's entourage)
Risk factors for Creutzfeldt-Jakob disease (history: treatment with extractive growth hormone, a family case of transmissible spongiform subacute encephalopathy, surgery with opening of the dura or neurosurgery or invasive brain exploration before 1 January 1995, stay in United Kingdom for a duration greater than 1 year cumulatively between 1980 and 1996 or the presence of neurological or neuropsychiatric scalable recent clinical signs)
Gastrointestinal disease:
Personal or 1st degree family history of: inflammatory bowel disease or celiac disease
Personal history of irritable bowel syndrome, idiopathic chronic constipation or chronic diarrhea
Previous history of gastrointestinal neoplasia or polyps
Family history of 1st degree gastrointestinal neoplasia or polyps before age 60
1st degree family history of one of the following autoimmune or inflammatory disease : inflammatory arthritis, psoriasis, multiple sclerosis, type I diabetes, spondylitis, lupus and Basedow disease
Previous history of :
Subject prone to hemorrhoids (at least 1 event within the previous 1 year)
Subject with an active chronic illness (except active chronic mild allergic disease o (example: allergic rhinitis, chronic eczema...))
Serious allergy requiring hospitalization within the previous 12 months
Curative long-term treatment
Severe allergy requiring hospitalization in the last 12 months
Allogeneic human or animal tissue or organ transplant
5- Factors that may affect the composition of the intestinal microbiota:
Special Diet (example: gluten-free...)
Lactose-free, vegetarian and vegan diets are permitted.
Pregnancy or breastfeeding
Taking immunosuppressants (eg calcineurin inhibitors, corticosteroids, biological agents, etc.)
Antineoplastic chemotherapy
6- Subject under legal protection 7- Participation in any other interventional study except studies for stool donation Temporary non-inclusion criteria
Infectious risk :
Unprotected sexual intercourse with a new partner in the previous 4 months and/or sexual intercourse with several different persons within the previous 4 months
sexual partner who has had more than 1 partner within the previous 4 months and/or
sexual transmitted infection within the previous 4 months (healthy volunteer donor himself or sexual partner)
Sexual relationship in exchange for money or drugs in the last 12 months. (healthy volunteer donor himself or sexual partner)
Sexual relationship with a partner with positive serology for HIV, viral hepatitis B or C, in the last 6 months.
Sexual relationship with a partner who has used intravenous drugs, doping substances
Hospitalization abroad for more than 24 hours in the last 12 months (healthy volunteer or entourage)
Travelling within the previous 3 months except : Germany, Austria, Belgium, Spain, Finland, Ireland, Italia, Luxembourg, Netherland, Portugal, Greece, Slovenia, Cyprus, Malta, Slovakia, Estonia , Bulgaria, Croatia , Hungary, Latvia , Lithuania, Poland , Romania, Czech Republic, the United Kingdom, Denmark, Norway, Sweden, Switzerland, USA or Canada.
Blood transfusion, piercing (including earrings) or tattoo within the previous 4 months
Surgery (all types) or hospitalization within the previous 4 months
Person living under the same roof with an infectious or contagious disease (i.e who have been hospitalized) within the previous 4 months
Blood exposure accident (for wound, pricking or projection ...) within the previous 4 months
Dental care within the previous 7 days
Gastroenteritis within the previous 3 months (defined by acute onset of diarrhea (> 3 soft or liquid stools per day) and duration < one week)
Episode of infection or skin infection/lesion within the previous 15 days 2-Risk linked to Covid-19
Confirmed infection in the previous 28 days (after symptoms have ceased)
Clinical signs of suspected infection (chill, cough, fever, dyspnea, myalgia, asthenia, malaise, pharyngeal pain, anosmia , ageusia, rhinorrhea, chest pain, headache, diarrhea) in the previous 28 days (after the end of symptoms)
Having been in risky contact (according to the definition of Santé Publique France with a person whose infection is confirmed or suspected: "14 days after the last risky contact: if the recommended screening tests in the event of risky contact between D15-D28 are negative "In the 28 days preceding inclusion in the absence of a screening test. Healthcare professionals using recommended protective measures with COVID patients are not considered high-risk contacts 3- Monkeypox risk
Confirmed or suspected infection within the previous 42 days ( after beginning of symptoms)
Risky contact with a person with confirmed or suspected infection within the previous 21 days (from the date of last contact)
Person who received the vaccine Imvanex within the previous 28 days ( after the last injection).
4- vaccination in the previous 15 days
5- Factors that may affect the composition of the intestinal microbiota:
Taking antibiotic or antifungal (oral) in the previous 3 months before donation
Taking non-steroidal anti-inflammatory drugs (oral) in the previous month before donation
Taking corticosteroids (oral) in the previous 4 weeks before donation. Corticosteroids allowed if taken more than 4 weeks before donation. and not for an autoimmune or inflammatory disease.
Temporary or permanent exclusion criteria:
Primary purpose
Allocation
Interventional model
Masking
400 participants in 1 patient group
Loading...
Central trial contact
Mélissa Montil, Praticien attaché; Harry SOKOL
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal